545 Concord Avenue
Suite 210
Cambridge, MA 02138
United States
857 702 9600
https://www.neurobopharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 8
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Hyung-Heon Kim | CEO, President, Principal Executive & Director | 625.16k | N/D | 1975 |
Mr. Marshall H. Woodworth | CFO, Principal Financial Officer & Principal Accounting Officer | 154.5k | N/D | 1958 |
Dr. Mi-Kyung Kim | Chief Scientific Officer | N/D | N/D | N/D |
Mr. Robert Homolka | Senior Vice President of Clinical Operations | N/D | N/D | N/D |
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
La calificación ISS Governance QuickScore de NeuroBo Pharmaceuticals, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.